

The Netherlands

A Small Country With **BIG** Ideas

With the European Medicines Agency moving to Amsterdam in 2019, there is a buzz about the Netherlands and its role in the future of biopharma. With the hub of all European regulatory decisions soon to be positioned in the country, and with Brexit looming a short three months away, it is expected that more innovative companies will see the appeal of Amsterdam and the wider regions. Here is what the country can offer those that want to be where the action is.

LIFE SCIENCES CLUSTERS

The country boasts the world's most concentrated life sciences and health clusters, based around the cities of Amsterdam, Rotterdam, Utrecht and Nijmegen.



3RD

IN THE WORLD FOR NUMBER OF BIOTECHNOLOGY PATENTS

8



UNIVERSITY MEDICAL CENTERS


12



RESEARCH UNIVERSITIES

7TH

IN THE WORLD FOR NUMBER OF PHARMACEUTICAL PATENTS




2,900

LIFE SCIENCES AND HEALTH COMPANIES IN A 200KM RADIUS

GATEWAY TO EUROPE

Guido Rasi, the EMA's director general discussed the "excellent connectivity" of Amsterdam as a factor when deciding to relocate the EMA there.



95%

OF EUROPE'S MAJOR MARKETS CAN BE REACHED WITHIN 24 HOURS



THE NETHERLANDS

42,500 km²
237 times smaller than the US

160m

CONSUMERS WHO CAN BE REACHED WITHIN A 300-MILE RADIUS

INVESTMENT AND OUTPUT

50


PUBLIC-PRIVATE-PARTNERSHIPS FUNDED BY

Health~Holland
SHARED CHALLENGES, SMART SOLUTIONS

€33bn

ANNUAL TURNOVER OF DUTCH BIOPHARMA INDUSTRY, WITH A PRODUCTION VALUE OF MORE THAN €29BN.

Clinical Drugs Trials Based In The Netherlands, By Phase (2017)



197

BIOTECH THERAPIES WERE DEVELOPED IN HOLLAND IN 2018, 97 AT THE PRECLINICAL STAGE, AND 11 IN PHASE III.